advertisement

Topcon

Journal of Ocular Pharmacology and Therapeutics 7

Showing records 1 to 7 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics

12068 Clinical evaluation of the intraocular pressure in patients with glaucoma or ocular hypertension by a self-assessable tonometer
Tai M-C; Chen P-L; Wu J-N; Lu D-W
Journal of Ocular Pharmacology and Therapeutics 2005; 21: 55-61
12085 Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: A preliminary study
Kook MS; Cho H-S; Yang SJ; Kim S; Chung J
Journal of Ocular Pharmacology and Therapeutics 2005; 21: 75-84
12096 Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma
Ozturk F; Ermis SS; Inan UU; Asagidag A; Yaman S
Journal of Ocular Pharmacology and Therapeutics 2005; 21: 68-74
11886 The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol
Miki H; Miki K
Journal of Ocular Pharmacology and Therapeutics 2004; 20: 509-517
11691 Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies
Bayer A; Weiler W; Oeverhaus U; Skrotzki F-E; Stewart WC
Journal of Ocular Pharmacology and Therapeutics 2004; 20: 470-478
11976 Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes
Sharif NA; Williams GW; Crider JY; Xu SX; Davis TL
Journal of Ocular Pharmacology and Therapeutics 2004; 20: 489-508
11996 Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment
Stewart WC; Konstas AGP; Pfeiffer N
Journal of Ocular Pharmacology and Therapeutics 2004; 20: 461-469

Issue 7-1

Change Issue


advertisement

Oculus